| Literature DB >> 25700742 |
Sarah L Mason1, Jiaxiang Zhang2, Faye Begeti3, Natalie Valle Guzman3, Alpar S Lazar3, James B Rowe4, Roger A Barker4, Adam Hampshire5.
Abstract
BACKGROUND: Deficits in emotional processing can be detected in the pre-manifest stage of Huntington's disease and negative emotion recognition has been identified as a predictor of clinical diagnosis. The underlying neuropathological correlates of such deficits are typically established using correlative structural MRI studies. This approach does not take into consideration the impact of disruption to the complex interactions between multiple brain circuits on emotional processing. Therefore, exploration of the neural substrates of emotional processing in pre-manifest HD using fMRI connectivity analysis may be a useful way of evaluating the way brain regions interrelate in the period prior to diagnosis.Entities:
Keywords: Amygdala; Effective connectivity; Reading the mind in the eyes; Theory of mind; fMRI
Mesh:
Substances:
Year: 2015 PMID: 25700742 PMCID: PMC4415907 DOI: 10.1016/j.neuropsychologia.2015.02.017
Source DB: PubMed Journal: Neuropsychologia ISSN: 0028-3932 Impact factor: 3.139
Demographic and clinical characteristics of all participants who completed Reading the Eyes in the Mind Task. Mean (standard deviation) reported unless otherwise stated. Between group comparisons were made using one way Analysis of Variance where appropriate.
| RMET | Combined | ||||||
|---|---|---|---|---|---|---|---|
| Control | PMGC | Early | Moderate | Late | PMCG | ||
| 26 | 29 | 12 | 18 | 20 | 11 | ||
| 59.0 | 43.5 (9.5) | 54.1 | 52.8 | 56.1 | 47.7 (13.2) | 0.001 | |
| 12:14 | 15:14 | 3:9 | 9:9 | 7:13 | 6:5 | ||
| 116.9 (5.1) | 111.9 (7.1) | 115.3 (7.9) | 112.4 (10.6) | 109.5 | 111.5 (9.2) | 0.34 ns | |
| 29.0 (1.3) | 29.2 (1.6) | 28.3 (1.2) | 27.5 (1.9) | 25.9 | 29.9 (0.4) | 0.001 | |
| 4.6 (3.8) | 7.8 (7.9) | 6.9 (6.6) | 11.4 (9.3) | 10.9 (5.4) | 6.5 (6.0) | 0.40 ns | |
| ND | 40.6 (14.00) | 30.2 (12.5) | 30.2 (15.1) | 18.8 (11.3) | 44.4 (18.8) | 0.001 | |
| N/A | 1.3 (2.2) | 16.4 | 21.8 | 37.5 | 1.5 (3.0) | 0.001 | |
| N/A | 25.1 (0.4) | 26.3 (1.2) | 29.4 | 35.6 | 25.0 (0.0) | 0.001 | |
Data are mean (standard deviation).
RMET & scanning=pre-manifest HD gene carriers who completed both studies.
Abbreviations – BDI: Beck Depression Inventory, FAS: verbal fluency, MMSE: Minimental State Exam, N/A: not applicable, NART: National Adult Reading Test, ND: not done, TFA: Total Functional Assessment, UHDRS: Unified Huntington's Disease Rating Scale,
Significantly different from controls, p<0.05.
Significantly different from pre-HD, p<0.05.
Clinical characteristics of the PMGC's. Mean (standard deviation) is tabulated unless otherwise stated. Between group comparisons using one-way Analysis of Variance.
| PMGC close | PMGC far | Control close | Control far | ||
|---|---|---|---|---|---|
| 10 | 10 | 12 | 11 | ||
| Gender (F:M) | 3:7 | 5:5 | 5:7 | 8:3 | |
| Age (years) | 49.6 (11.4) | 41.5 (9.8) | 45.0 (13.6) | 38.7 (11.1) | 0.17 (ns) |
| CAG repeat length | 42.1 (2.5) | 40.3 (1.3) | n/a | n/a | 0.1 (ns) |
| Estimated time to onset | 10.5 (2.9) | 23.8 (6.9) | n/a | n/a | 0.001 |
| Disease burden score | 293.4 (58.6) | 176.4 (37.0) | n/a | n/a | 0.001 |
| UHDRS | 3.3 (2.5) | 0.4 (1.0) | n/a | n/a | 0.003 |
| Diagnostic confidence score | 1.0 (1.1) | 0.2 (0.4) | n/a | n/a | 0.039 |
Abbreviations – CAG: cytosine–adenine–guanine, UHDRS: Unified Huntington's Disease Rating Scale,
Fig. 1PPI GLM statistical parametrical maps. (A) Positive PPI effects originating from the amygdala during exposure to ‘angry faces’ relative to ‘neutral faces’ for all participants at a liberal threshold (p<0.001 uncorrected, cluster size 50 voxels or more). (B) Decreased PPI connectivity in PMGC's during exposure to ‘angry faces’ relative to ‘neutral faces’ (p<0.05, cluster level corrected).
Fig. 2Correlation between PPI connectivity originating from the amygdala to the right fusiform facial area and (A) estimated years to disease onset and (B) disease burden score in PMGC's. Participants have be divided into “close” to and “far” from onset groups and further subdivided into pre-manifest, intermediate and confirmed groups to visually represent those gene carriers who have received (confirmed) or are anticipated to imminently receive a diagnosis of HD (intermediate) since scanning. Error bars show the standard errors across all healthy controls. The regression line (solid) and the 95% confidence intervals (dashed) are shown.
Fig. 3Behavioural performance on the Reading the Mind in the Eyes task stratified by disease stage for all HD participants. ⁎ indicates a significant difference compared to controls at the p=0.05 level.
Fig. 4Performance on the Reading the Mind in the Eyes Tasks correlated with total functional assessment score from the UHDRS.
Fig. 5Correlation between performance on the Reading the Mind in the Eyes task and (A) the estimated number of years to disease onset and (B) the disease burden score in PMGC's.
Fig. 6Correlation between PPI connectivity between the amygdala and the right fusiform facial area and performance on the Reading the Mind in the Eyes Task in PMGC's. The regression line (solid) and the 95% confidence intervals (dashed) are shown.